NASDAQ: JUNS
Jupiter Neurosciences Inc Stock

$0.83-0.02 (-2.35%)
Updated Feb 14, 2025
JUNS Price
$0.83
Fair Value Price
-$0.07
Market Cap
$27.51M
52 Week Low
$0.78
52 Week High
$19.51
P/E
N/A
P/B
-4.78x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.02
Operating Cash Flow
N/A
Beta
0.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

JUNS Overview

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine JUNS's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
JUNS
Ranked
#78 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important JUNS news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JUNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

JUNS ($0.83) is overvalued by 1,330.64% relative to our estimate of its Fair Value price of -$0.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
JUNS ($0.83) is not significantly undervalued (1,330.64%) relative to our estimate of its Fair Value price of -$0.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
JUNS's short-term liabilities ($5.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more JUNS due diligence checks available for Premium users.

Valuation

JUNS fair value

Fair Value of JUNS stock based on Discounted Cash Flow (DCF)

Price
$0.83
Fair Value
-$0.07
Undervalued by
1,329.15%
JUNS ($0.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
JUNS ($0.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

JUNS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-4.78x
Industry
4.77x

JUNS's financial health

Profit margin

Revenue
$0.0
Net Income
-$591.0k
Profit Margin
0%

Assets to liabilities

Assets
$85.5k
Liabilities
$5.8M
Debt to equity
-1.02
JUNS's short-term liabilities ($5.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JUNS's long-term liabilities ($155.69k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JUNS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JUNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$42.6k
Investing
$0.0
Financing
$28.0k

JUNS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
JUNSC$27.51M-2.00%N/A-4.78x
CRISC$27.26M+2.55%-0.41x-3.12x
CDIOD$27.05M-1.18%-2.09x7.34x
ALLK$27.96M+5.03%-0.15x0.38x
LEXXF$28.08M+4.58%-3.20x2.87x

Jupiter Neurosciences Stock FAQ

What is Jupiter Neurosciences's quote symbol?

(NASDAQ: JUNS) Jupiter Neurosciences trades on the NASDAQ under the ticker symbol JUNS. Jupiter Neurosciences stock quotes can also be displayed as NASDAQ: JUNS.

If you're new to stock investing, here's how to buy Jupiter Neurosciences stock.

What is the 52 week high and low for Jupiter Neurosciences (NASDAQ: JUNS)?

(NASDAQ: JUNS) Jupiter Neurosciences's 52-week high was $19.51, and its 52-week low was $0.78. It is currently -95.74% from its 52-week high and 6.54% from its 52-week low.

How much is Jupiter Neurosciences's stock price per share?

(NASDAQ: JUNS) Jupiter Neurosciences stock price per share is $0.83 today (as of Feb 14, 2025).

What is Jupiter Neurosciences's Market Cap?

(NASDAQ: JUNS) Jupiter Neurosciences's market cap is $27.51M, as of Feb 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Jupiter Neurosciences's market cap is calculated by multiplying JUNS's current stock price of $0.83 by JUNS's total outstanding shares of 33,103,860.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.